(-0.41%) 5 460.48 points
(-0.12%) 39 119 points
(-0.71%) 17 733 points
(-0.34%) $81.46
(-3.13%) $2.60
(0.01%) $2 336.90
(0.61%) $29.44
(0.28%) $1 009.00
(-0.06%) $0.933
(0.45%) $10.68
(-0.05%) $0.791
(0.86%) $85.73
Live Chart Being Loaded With Signals
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules...
Stats | |
---|---|
Šios dienos apimtis | 146 000 |
Vidutinė apimtis | 187 414 |
Rinkos kapitalizacija | 175.47M |
EPS | $-0.140 ( Q1 | 2024-05-08 ) |
Kita pelno data | ( $-0.0900 ) 2024-08-05 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-2.83 (Sector) 42.63 (Industry) 0 |
ATR14 | $0.00400 (0.26%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-21 | Watts Charles M | Buy | 46 686 | Restricted Stock Units |
2024-05-21 | Watts Charles M | Buy | 37 050 | Stock Options (Right to Buy) |
2024-05-23 | Vazquez Chris | Buy | 880 | Common Stock |
2024-05-23 | Vazquez Chris | Sell | 22 | Series A Non-Voting Convertible Preferred Stock |
2024-05-23 | Strobeck Matthew | Buy | 295 680 | Common Stock |
INSIDER POWER |
---|
86.54 |
Last 100 transactions |
Buy: 7 725 095 | Sell: 600 698 |
Tūris Koreliacija
Biodesix, Inc. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
TBNK | 0.942 |
LBRDA | 0.934 |
PTSI | 0.934 |
LBRDK | 0.932 |
EBMT | 0.928 |
FFIC | 0.928 |
LTRX | 0.928 |
GBLMX | 0.927 |
VLCN | 0.924 |
CNOB | 0.923 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
OZEM | -1 |
MTTR | -0.944 |
HLP | -0.941 |
FEBO | -0.934 |
EZPW | -0.921 |
MAMA | -0.916 |
MCAAW | -0.915 |
FAAR | -0.915 |
BRKHW | -0.912 |
MOR | -0.912 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Biodesix, Inc. Koreliacija - Valiuta/Žaliavos
Biodesix, Inc. Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $49.09M |
Bruto pelnas: | $33.21M (67.66 %) |
EPS: | $-0.640 |
FY | 2023 |
Pajamos: | $49.09M |
Bruto pelnas: | $33.21M (67.66 %) |
EPS: | $-0.640 |
FY | 2022 |
Pajamos: | $38.21M |
Bruto pelnas: | $24.06M (62.96 %) |
EPS: | $-1.910 |
FY | 2021 |
Pajamos: | $54.51M |
Bruto pelnas: | $54.51M (100.00 %) |
EPS: | $-1.580 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Biodesix, Inc.
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.